Protalix Reports Preclinical Data On Anti-TNF Follow-on Biologic Arthritis Drug
Links shared publicly online about this topic.
- 1,726total visits
Protalix Reports Preclinical Data On Anti-TNF Follow-on Biologic Arthritis Drug
Protalix biotherapeutics, inc. (nyse-amex: plx), reported preclinical data on pr-antitnf, a biosimilar version of etanercept (enbrel™). produced using the company's proprietary procellex&tra
View full resource at medicalnewstoday.com
Tags: Arthritis, Arthritis Medication, Rheumatoid Arthritis Medication, Drug, Enbrel
Most Recently Shared on September 24, 2009 at 10:46 am By:
Protalix Reports Preclinical Data On Anti-TNF Follow-on Biologic Arthritis Drug: Protalix Biotherapeutics, Inc. .. http://bit.ly/WdV9C
Advertisement
